A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Trial Profile

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Hereditary nephritis; Renal failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CARDINAL
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2017 According to a Reata Pharmaceuticals media release, one year data from the study are expected to be available during the second half of 2019.
    • 07 Aug 2017 According to a Reata Pharmaceuticals media release, first patient has been enrolled in phase 3 portion of this trial.
    • 24 Jul 2017 According to a Reata Pharmaceuticals media release,final data from the Phase 2of this trial will be available in 2H17 and the sample size of the Phase 3 study has been adjusted from 180 patients to 150 patients.The Company expects data from the Week 48 and Week 52 of phase 3 analyses during 2H19.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top